Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2019-10-16 | Reverse | 1:10 |
Profound Medical Corp. develops MRI-guided ablation devices like TULSA-PRO and Sonalleve for treating prostate disease, fibroids, and pain across Canada, Germany, the U.S., and Finland.

The TULSA-PRO® is an MRI-guided, radiation-free medical device for customizable prostate tissue ablation, treating prostate cancer and BPH while protecting surrounding tissue.
| Icon | PRODUCT | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | Recurring NonCapital | $4.07M | $2.3M ▼ | $2.47M ▲ | $1.61M ▼ |
![]() | Capital Equipment | $1.22M | $3.67M ▲ | $2.86M ▼ | $871K ▼ |
| Map | REGION | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | UNITED STATES | $5M | $3.72M ▼ | $1.62M ▼ | $1.75M ▲ |
![]() | CANADA | $570K | $1.94M ▲ | $3.57M ▲ | $556K ▼ |
![]() | GERMANY | $168K | $465K ▲ | $150K ▼ | $182K ▲ |
Overall rating: C-
| PEER | PRICE | |
|---|---|---|
AVR | $8.59 | COMPARE |
PRE | $25.84 | COMPARE |
TLSI | $4.97 | COMPARE |
STIM | $2.75 | COMPARE |
MXCT | $1.24 | COMPARE |
LNSR | $8.29 | COMPARE |
OWLT | $4.98 | COMPARE |
NNOX | $0.73 | COMPARE |